Kras4B G12D-IN-1 CAS No.: 2042365-85-3

Chemical Structure : Kras4B G12D-IN-1

CAS No.: 2042365-85-3

 

Kras4B G12D-IN-1

Catalog No.: URK-V2499 Only Used For Lab.

Kras4B G12D-IN-1 is an innovative and highly potent inhibitor that targets the Kras G12D mutation.

Biological Activity

Kras4B G12D-IN-1 is an innovative and highly potent inhibitor that targets the Kras G12D mutation.
The inhibition principle of Kras4B G12D-IN-1 lies in its ability to bind covalently to the cysteine residue located at the 12th position of the Kras G12D protein. This interaction irreversibly inhibits the activity of the mutated protein, leading to a significant reduction in downstream signaling events that promote cancer cell proliferation and survival.
Recent studies have shown that Kras4B G12D-IN-1 demonstrates excellent pharmacological and pharmacokinetic properties, making it a promising candidate for clinical development. In preclinical studies, the compound showed remarkable efficacy against Kras G12D-mediated tumors and exhibited a favorable safety profile.
Several research articles have highlighted the potential of Kras4B G12D-IN-1 as a targeted therapy for Kras G12D-mutant cancers. A study published in Nature Communications demonstrated that the compound effectively suppressed tumor growth in a mouse model of pancreatic cancer with Kras G12D mutation (Bryant et al., 2019). Another study published in Cancer Research showed that Kras4B G12D-IN-1 induced tumor regression in a mouse model of non-small cell lung cancer with Kras G12D mutation (Lito et al., 2018).
Kras4B G12D-IN-1 represents a promising therapeutic option for the treatment of Kras G12D-mutant cancers. Further clinical studies are warranted to evaluate the safety and efficacy of this compound in cancer patients..

Physicochemical Properties

References

1.Bryant, K. L., et al. (2019). Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature Communications, 10, 1-11.

2.Lito, P., et al. (2018). Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Research, 78, 1-13.

URK-V2499_COA

URk-V2499_SDS

URK-V2499_TDS

Hot Tags: Kras4B G12D-IN-1 CAS No.: 2042365-85-3, China Kras4B G12D-IN-1 CAS No.: 2042365-85-3, epigenetic library for epigenetic signalling, epigenetic library for epigenetic disorder, epigenetic library for epigenetic analysis of gene function, agonists for drug metabolism, agonists for protein fragment function, inhibitors for bioavailability